ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,631Medicare Part D Prescriptions Filled, Including Refills

Rank: 158 out of 625

$421K Total Retail Price of All Prescriptions

Rank: 249 out of 625

430 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Carolina
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 430 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

8% of this provider’s 430 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 7,064 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $62 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Carolina
LEVOTHYROXINE SODIUM 500 433 1 3
SIMVASTATIN 438 381 2 2
AMLODIPINE BESYLATE 427 391 3 1
LISINOPRIL 320 273 4 5
LISINOPRIL-HYDROCHLOROTHIAZIDE 233 206 5 27
GLIMEPIRIDE 203 190 6 42
GABAPENTIN 189 140 7 14
OMEPRAZOLE 188 135 8 6
FUROSEMIDE 187 157 9 7
METFORMIN HCL 178 153 10 10
METOPROLOL SUCCINATE 152 127 11 15
SPIRONOLACTONE 148 117 12 64
LOSARTAN POTASSIUM 141 132 13 18
CRESTOR 140 114 14 17
METFORMIN HCL ER 138 112 15 41
METOPROLOL TARTRATE 137 136 16 11
WARFARIN SODIUM 136 134 17 20
LOSARTAN-HYDROCHLOROTHIAZIDE 136 124 17 38
AMLODIPINE BESYLATE-BENAZEPRIL 128 124 19 48
HYDROCODONE-ACETAMINOPHEN 107 82 S3 20 4
AMITRIPTYLINE HCL 107 85 R 20 61
TAMSULOSIN HCL 99 72 22 36
JANUMET 97 75 23 163
FLUTICASONE PROPIONATE 85 68 24 32
ALENDRONATE SODIUM 84 65 25 34
CLONIDINE HCL 82 71 26 50
CARVEDILOL 76 67 27 23
ATENOLOL 75 67 28 22
TRAZODONE HCL 74 42 29 51
PAROXETINE HCL 71 66 30 76
HYDROCHLOROTHIAZIDE 69 62 31 12
LANTUS 66 58 32 54
CYMBALTA 62 44 33 46
CITALOPRAM HBR 61 56 34 24
NEXIUM 59 26 35 21
DONEPEZIL HCL 58 58 36 33
ATORVASTATIN CALCIUM 57 44 37 9
NAPROXEN 56 56 38 104
JANUVIA 54 45 39 74
PRAVASTATIN SODIUM 52 39 40 8
FLUOXETINE HCL 52 24 40 62
POTASSIUM CHLORIDE 51 36 42 19
OXYCODONE-ACETAMINOPHEN 50 41 S2 43 95
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 23, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.